A recent study from the USA assessing commercially insured children identified a declining trend in the new use of cDMARDs in JIA, paralleled by an increasing trend in use of the bDMARDs [ 48 ], which reflects advances in therapeutic strategies in JIA.cDMARDs used in paediatric systemic RMDs Various cDMARDs have been used in paediatric RMDs, including cSLE, JDM, systemic sclerosis, vasculitis or childhood-onset Sjögren’s disease (cSjD) associated with refractory manifestations or organ involvement, such as MMF, MTX, azathioprine (AZA), ciclosporin, tacrolimus (TAC) and cyclophosphamide (CYC).
← all excerpts
The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care.
1
—
—